Clinical Trials Logo

Clinical Trial Summary

To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06119490
Study type Interventional
Source Fujian Provincial Hospital
Contact Chao Ji
Phone +86 18651619908
Email jichaofy@fjmu.edu.cn
Status Recruiting
Phase Early Phase 1
Start date July 5, 2023
Completion date September 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04711200 - LYell SYndrome MEsenchymal Stromal Cells Treatment Phase 1/Phase 2
Completed NCT01696500 - Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Phase 3
Terminated NCT02037347 - Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Phase 1/Phase 2
Withdrawn NCT02795143 - Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study N/A
Withdrawn NCT02319616 - Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Phase 1/Phase 2
Withdrawn NCT00372723 - Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) Phase 2
Recruiting NCT02574988 - Severe Cutaneous Adverse Reactions in Thailand
Not yet recruiting NCT03585946 - Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis